Market Cap$25.94B
P/E26.15x
PEG Ratio1.53
Div yield2.10%
Beta0.56
DGX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)11.13%
Price vs S&P 500 (4W)-2.71%
PEG Ratio1.53
VGM Score51.69
P/E Ratio (Annual)26.15x
Indicated Dividend Yield (Annual)2.10%
DGX Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $2.82 | $3.12 | +10.51%(+$0.30) | |
| Q1 2026 | $2.37 | $2.50 | +5.61%(+$0.13) | |
| Q4 2025 | $2.36 | $2.42 | +2.63%(+$0.06) | |
| Q3 2025 | $2.50 | $2.60 | +3.85%(+$0.10) | |
| Q2 2025 | $2.57 | $2.62 | +1.87%(+$0.05) |
DGX Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
3.79
3.83
3.83
3.83
Industry Peers — Health Services(30)
| Symbol | Value Score | Growth Score | Momentum Score | P/E Ratio (Annual) | Revenue Growth TTM (YoY) | Operating Margin (TTM) | ROE (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
DGXQuest Diagnostics Inc. | C | D | B | 26.1x | 9.9% | 14.1% | 14.5% | $235.00 |
| NTRANatera, Inc. Common Stock | F | A | A | — | 37.8% | -10.7% | -11.7% | $393.44 |
| LHLabcorp Holdings Inc. | C | D | B | 29.4x | 6.4% | 10.4% | 11.6% | $317.95 |
| GHGuardant Health, Inc. Common Stock | F | A | B | — | 42.7% | -40.2% | -246.6% | $158.60 |
| CAICaris Life Sciences, Inc. Common Stock | F | A | B | — | 38.5% | 12.7% | 18.8% | $30.56 |
| RDNTRadNet, Inc. Common Stock | D | C | C | 1779.3x | 18.9% | 3.0% | -1.9% | $68.80 |
| GRALGRAIL, Inc. Common Stock | D | B | B | — | 23.1% | -338.4% | -15.9% | $117.81 |
| BLLNBillionToOne, Inc. Class A Common Stock | F | F | C | 621.1x | — | 10.9% | 8.9% | $98.12 |
| VCYTVeracyte, Inc. | D | B | C | 52.2x | 17.3% | 19.6% | 8.6% | $43.12 |
| CDNACareDx, Inc. | D | B | A | 18.3x | 34.4% | 23.6% | 32.8% | $64.00 |
| CELCCelcuity Inc. Common Stock | — | — | D | — | — | — | -244.6% | $56.58 |
About Quest Diagnostics Inc.
Quest Diagnostics is the leading independent provider of diagnostic testing services in the United States, generating over 97% of revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse screening delivered via a nationwide network of approximately 2,400 patient service centers and partnerships with healthcare providers. The company's diagnostic solutions segment provides supplementary services including clinical trials testing, risk-assessment services, and healthcare information technology solutions.